853 related articles for article (PubMed ID: 15823578)
1. Binding affinity difference induced by the stereochemistry of the sulfoxide bridge of the cyclic peptide inhibitors of Grb2-SH2 domain: NMR studies for the structural origin.
Shi YH; Song YL; Lin DH; Tan J; Roller PP; Li Q; Long YQ; Song GQ
Biochem Biophys Res Commun; 2005 May; 330(4):1254-61. PubMed ID: 15823578
[TBL] [Abstract][Full Text] [Related]
2. Solution structure and dynamics of G1TE, a nonphosphorylated cyclic peptide inhibitor for the Grb2 SH2 domain.
Lou YC; Lung FD; Pai MT; Tzeng SR; Wei SY; Roller PP; Cheng JW
Arch Biochem Biophys; 1999 Dec; 372(2):309-14. PubMed ID: 10600169
[TBL] [Abstract][Full Text] [Related]
3. Structural and conformational requirements for high-affinity binding to the SH2 domain of Grb2(1).
Ettmayer P; France D; Gounarides J; Jarosinski M; Martin MS; Rondeau JM; Sabio M; Topiol S; Weidmann B; Zurini M; Bair KW
J Med Chem; 1999 Mar; 42(6):971-80. PubMed ID: 10090780
[TBL] [Abstract][Full Text] [Related]
4. Crystal structures of the SH2 domain of Grb2: highlight on the binding of a new high-affinity inhibitor.
Nioche P; Liu WQ; Broutin I; Charbonnier F; Latreille MT; Vidal M; Roques B; Garbay C; Ducruix A
J Mol Biol; 2002 Feb; 315(5):1167-77. PubMed ID: 11827484
[TBL] [Abstract][Full Text] [Related]
5. Solution structure of the C-terminal SH2 domain of the p85 alpha regulatory subunit of phosphoinositide 3-kinase.
Siegal G; Davis B; Kristensen SM; Sankar A; Linacre J; Stein RC; Panayotou G; Waterfield MD; Driscoll PC
J Mol Biol; 1998 Feb; 276(2):461-78. PubMed ID: 9512716
[TBL] [Abstract][Full Text] [Related]
6. Surface plasmon resonance thermodynamic and kinetic analysis as a strategic tool in drug design. Distinct ways for phosphopeptides to plug into Src- and Grb2 SH2 domains.
de Mol NJ; Dekker FJ; Broutin I; Fischer MJ; Liskamp RM
J Med Chem; 2005 Feb; 48(3):753-63. PubMed ID: 15689159
[TBL] [Abstract][Full Text] [Related]
7. Backbone dynamics of the C-terminal SH2 domain of the p85alpha subunit of phosphoinositide 3-kinase: effect of phosphotyrosine-peptide binding and characterization of slow conformational exchange processes.
Kristensen SM; Siegal G; Sankar A; Driscoll PC
J Mol Biol; 2000 Jun; 299(3):771-88. PubMed ID: 10835283
[TBL] [Abstract][Full Text] [Related]
8. Global optimization of conformational constraint on non-phosphorylated cyclic peptide antagonists of the Grb2-SH2 domain.
Long YQ; Lung FD; Roller PP
Bioorg Med Chem; 2003 Sep; 11(18):3929-36. PubMed ID: 12927853
[TBL] [Abstract][Full Text] [Related]
9. Design and synthesis of conformationally constrained Grb2 SH2 domain binding peptides employing alpha-methylphenylalanyl based phosphotyrosyl mimetics.
Oishi S; Karki RG; Kang SU; Wang X; Worthy KM; Bindu LK; Nicklaus MC; Fisher RJ; Burke TR
J Med Chem; 2005 Feb; 48(3):764-72. PubMed ID: 15689160
[TBL] [Abstract][Full Text] [Related]
10. Solution structure of the SH2 domain of Grb2 complexed with the Shc-derived phosphotyrosine-containing peptide.
Ogura K; Tsuchiya S; Terasawa H; Yuzawa S; Hatanaka H; Mandiyan V; Schlessinger J; Inagaki F
J Mol Biol; 1999 Jun; 289(3):439-45. PubMed ID: 10356320
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of macrocyclic Grb2 SH2 domain-binding peptide mimetics prepared by ring-closing metathesis of C-terminal allylglycines with an N-terminal beta-vinyl-substituted phosphotyrosyl mimetic.
Oishi S; Karki RG; Shi ZD; Worthy KM; Bindu L; Chertov O; Esposito D; Frank P; Gillette WK; Maderia M; Hartley J; Nicklaus MC; Barchi JJ; Fisher RJ; Burke TR
Bioorg Med Chem; 2005 Apr; 13(7):2431-8. PubMed ID: 15755645
[TBL] [Abstract][Full Text] [Related]
12. Utilization of a beta-aminophosphotyrosyl mimetic in the design and synthesis of macrocyclic Grb2 SH2 domain-binding peptides.
Lee K; Zhang M; Liu H; Yang D; Burke TR
J Med Chem; 2003 Jun; 46(13):2621-30. PubMed ID: 12801226
[TBL] [Abstract][Full Text] [Related]
13. Potent inhibition of Grb2 SH2 domain binding by non-phosphate-containing ligands.
Yao ZJ; King CR; Cao T; Kelley J; Milne GW; Voigt JH; Burke TR
J Med Chem; 1999 Jan; 42(1):25-35. PubMed ID: 9888830
[TBL] [Abstract][Full Text] [Related]
14. Small nonphosphorylated Grb2-SH2 domain antagonists evaluated by surface plasmon resonance technology.
Lung FD; Chang CW; Chong MC; Liou CC; Li P; Peach ML; Nicklaus MC; Lou BS; Roller PP
Biopolymers; 2005; 80(5):628-35. PubMed ID: 15660381
[TBL] [Abstract][Full Text] [Related]
15. Structural basis for the high affinity of amino-aromatic SH2 phosphopeptide ligands.
Rahuel J; García-Echeverría C; Furet P; Strauss A; Caravatti G; Fretz H; Schoepfer J; Gay B
J Mol Biol; 1998 Jun; 279(4):1013-22. PubMed ID: 9642078
[TBL] [Abstract][Full Text] [Related]
16. Functional preference of the constituent amino acid residues in a phage-library-based nonphosphorylated inhibitor of the Grb2-SH2 domain.
Lung FD; Long YQ; Roller PP; King CR; Varady J; Wu XW; Wang S
J Pept Res; 2001 Jun; 57(6):447-54. PubMed ID: 11437948
[TBL] [Abstract][Full Text] [Related]
17. Nuclear magnetic resonance solution structure of the growth factor receptor-bound protein 2 Src homology 2 domain.
Thornton KH; Mueller WT; McConnell P; Zhu G; Saltiel AR; Thanabal V
Biochemistry; 1996 Sep; 35(36):11852-64. PubMed ID: 8794768
[TBL] [Abstract][Full Text] [Related]
18. Grb2 SH2 domain-binding peptide analogs as potential anticancer agents.
Lung FD; Tsai JY
Biopolymers; 2003; 71(2):132-40. PubMed ID: 12767115
[TBL] [Abstract][Full Text] [Related]
19. Structural requirements for Tyr in the consensus sequence Y-E-N of a novel nonphosphorylated inhibitor to the Grb2-SH2 domain.
Long YQ; Yao ZJ; Voigt JH; Lung FD; Luo JH; Burke TR; King CR; Yang D; Roller PP
Biochem Biophys Res Commun; 1999 Nov; 264(3):902-8. PubMed ID: 10544028
[TBL] [Abstract][Full Text] [Related]
20. The three-dimensional solution structure of the SH2 domain from p55blk kinase.
Metzler WJ; Leiting B; Pryor K; Mueller L; Farmer BT
Biochemistry; 1996 May; 35(20):6201-11. PubMed ID: 8639560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
